Clostridium butyricum Modulates the Microbiome to Protect Intestinal Barrier Function in Mice with Antibiotic-Induced Dysbiosis

Abstract

Clostridium butyricum MIYAIRI 588 (CBM 588) is a probiotic bacterium that has previously been used to prevent antibiotic-associated diarrhea. However, the underlying mechanism by which CBM 588 protects the gut epithelial barrier remains unclear. Here, we show that CBM 588 increased the abundance of Bifidobacterium, Lactobacillus, and Lactococcus species in the gut microbiome and also enhanced the intestinal barrier function of mice with antibiotic-induced dysbiosis. Additionally, CBM 588 significantly promoted the expansion of IL-17A-producing gdT cells and IL-17A-producing CD4 cells in the colonic lamina propria (cLP), which was closely associated with changes in the intestinal microbial composition. Additionally, CBM 588 plays an important role in controlling antibiotic-induced gut inflammation through upregulation of anti-inflammatory lipid metabolites such as palmitoleic acid, 15d-prostaglandin J 2 , and protectin D 1 . This study reveals a previously unrecognized mechanism of CBM 588 and provides new insights into gut epithelial barrier protection with probiotics under conditions of antibiotic-induced dysbiosis.

The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine–Dependent but GPR43/109a-Independent Mechanisms

“…Another potential mechanism for the protective effect of CBM588 is the strengthening of barrier immunity by SCFA, as reported previously (50). Reg3b and -g are antimicrobial peptides that protect the gut epithelial barrier from pathogenic bacteria (51).…”

A gut butyrate‑producing bacterium <em>Butyricicoccus&nbsp;pullicaecorum</em> regulates short‑chain fatty acid transporter and receptor to reduce the progression of 1,2‑dimethylhydrazine‑associated colorectal cancer

“…The importance of probiotics in the prevention and treatment of CRC has been studied ( 61 ) and there is increasing evidence of the clinical significance of butyrate-producing gut microbes ( 44 , 62 , 63 ). For instance, another butyrate-producing probiotic in the same family of B. pullicaecorum, Clostridium butyricum , has been demonstrated to prevent tumor development in the intestinal barrier ( 64 , 65 ). Other families (e.g.…”

Microbial modulation of intestinal T helper cell responses and implications for disease and therapy

“…In fact, it is now recognized that the immunomodulatory effects of dysbiosis are predominantly mediated through changes in the overall metabolic function of the microbiota resulting in an altered overall metabolite profile. 11 While it is clear that the microbiota also interacts with other T cell subsets, such as intraepithelial lymphocytes (IEL), 12 γδ-T cells, 13,14 and MAIT cells, 15,16 as well as non T cell populations, 2 this review will focus on the intestinal CD4 T cell compartment. We will also highlight the impact of microbial CD4 T cell antigen mimicry in autoimmune disease and the role of the microbiota in cancer immune checkpoint blockade (ICB) therapy as examples of mechanistic (and immunological) links between intestinal CD4 T cells, microbes, and metabolites.…”